Pfizer Inc. received a warning letter from the U.S. Food and Drug Administration after inspectors found “significant violations” at a manufacturing plant for drugs made by its Hospira unit.
The inspection, conducted over about three weeks in May and June last year at a McPherson, Kansas, drug plant, found “significant violations of current good manufacturing practice” rules, according to a Feb. 14 letter released by the agency Tuesday. Pfizer acquired the plant with its about $17 billion takeover of Hospira in 2015.
